Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival.
Spreafico A, Coate L, Zhai R, Xu W, Chen ZF, Chen Z, Patel D, Tse B, Brown MC, Heist RS, Dodbiba L, Teichman J, Kulke M, Su L, Eng L, Knox J, Wong R, Darling GE, Christiani DC, Liu G. Spreafico A, et al. Among authors: coate l. Cancer Epidemiol. 2017 Apr;47:28-34. doi: 10.1016/j.canep.2016.11.009. Epub 2017 Jan 12. Cancer Epidemiol. 2017. PMID: 28088657
Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer.
Coate LE, Massey C, Hope A, Sacher A, Barrett K, Pierre A, Leighl N, Brade A, de Perrot M, Waddell T, Liu G, Feld R, Burkes R, Cho BC, Darling G, Sun A, Keshavjee S, Bezjak A, Shepherd FA. Coate LE, et al. J Thorac Oncol. 2011 Mar;6(3):537-44. doi: 10.1097/JTO.0b013e31820b8b9b. J Thorac Oncol. 2011. PMID: 21258243 Free article.
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.
Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF; EMPHASIS-lung Collaborative Group. Peters S, et al. Among authors: coate l. J Thorac Oncol. 2017 Apr;12(4):752-762. doi: 10.1016/j.jtho.2016.12.017. Epub 2016 Dec 23. J Thorac Oncol. 2017. PMID: 28017787 Free article. Clinical Trial.
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S; ETOP 10-16 BOOSTER Collaborators. Soo RA, et al. Among authors: coate l. Ann Oncol. 2022 Feb;33(2):181-192. doi: 10.1016/j.annonc.2021.11.010. Epub 2021 Nov 26. Ann Oncol. 2022. PMID: 34839016 Free article. Clinical Trial.
Pregnancy-associated breast cancer: evaluating maternal and foetal outcomes. A national study.
Prior L, O'Dwyer R, Farooq AR, Greally M, Ward C, O'Leary C, Aslam R, Darwish W, Ahmed N, Othman EC, Watson G, Kelly D, Gleeson J, Kiely L, Hassan A, Walsh EM, O'Reilly D, Jones A, Featherstone H, Lim M, Murray H, Hennessy BT, Smyth LM, Leonard G, Grogan L, Breathnach O, Calvert P, Horgan AM, Coate L, Jordan EJ, O'Mahony D, Gupta R, Keane MM, Westrup J, Duffy K, O'Connor M, Morris PG, Kennedy MJ, O'Reilly S, McCaffrey J, Kelly CM, Carney D, Gullo G, Crown J, Higgins MJ, Walsh PM, Walshe JM. Prior L, et al. Among authors: coate l. Breast Cancer Res Treat. 2021 Aug;189(1):269-283. doi: 10.1007/s10549-021-06263-y. Epub 2021 Jun 14. Breast Cancer Res Treat. 2021. PMID: 34125341
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial.
Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M, Rodriguez-Abreu D, Falchero L, Moran T, Ortega Granados AL, Monnet I, Mohorcic K, Sureda BM, Betticher D, Demedts I, Macias JA, Cuffe S, Luciani A, Sanchez JG, Curioni-Fontecedro A, Gautschi O, Price G, Coate L, von Moos R, Zielinski C, Provencio M, Menis J, Ruepp B, Pochesci A, Roschitzki-Voser H, Besse B, Rabaglio M, O'Brien MER, Stahel RA. Peters S, et al. Among authors: coate l. J Thorac Oncol. 2020 Oct;15(10):1647-1656. doi: 10.1016/j.jtho.2020.06.011. Epub 2020 Jun 18. J Thorac Oncol. 2020. PMID: 32565388 Free article. Clinical Trial.
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group. Rosell R, et al. Among authors: coate l. Lancet Respir Med. 2017 May;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. Epub 2017 Apr 10. Lancet Respir Med. 2017. PMID: 28408243 Clinical Trial.
39 results